FDA warning letter: Boston Scientific's post-Guidant euphoria short-lived
This article was originally published in Clinica
Executive Summary
Just two days after wresting Guidant over from Johnson & Johnson, Boston Scientific could find the deal it fought so hard to win in jeopardy after the company received a warning letter from the FDA concerning its overall corporate quality management system.